FORT WORTH, Texas — Alcon has announced the U.S. commercial availability of TRYPTYR (acoltremon ophthalmic solution) 0.003%, the latest innovation for the treatment of the signs and symptoms of Dry Eye Disease (DED). Approved by the U.S. Food and Drug Administration (FDA) in May, Eye Care Professionals (ECPs) across the U.S. can officially begin prescribing TRYPTYR to their patients, expanding their DED treatment options for the more than 30 million Americans suffering with dry eye symptoms.
“TRYPTYR is highly anticipated in the Dry Eye Disease treatment space as the first neuromodulator eye drop to rapidly increase natural tear production, as early as day one,” said Lisa Praeger, Vice President, General Manager, U.S. Ocular Health Pharmaceutical, Alcon. “As the global eye care leader with a comprehensive portfolio of dry eye products—from over-the-counter offerings to prescription therapies—Alcon is uniquely positioned to deliver this innovation to Eye Care Professionals and the millions of patients who need Dry Eye Disease relief. Leveraging our deep commercial expertise and specialized sales force, we’re excited to give broader access to this important new treatment option.”
Many commonly used DED treatment options have limitations, including slow onset. Among surveyed dry eye patients, only 13% felt their dry eye was well managed.* A first-in-class TRPM8 receptor agonist (neuromodulator), TRYPTYR demonstrated statistically significant increase in natural tear production as early as Day 1.
“Understanding patients’ Dry Eye Disease struggles allow us to make informed
recommendations on how to best manage their symptoms and create an effective ongoing disease management plan,” said Paul Karpecki, OD, Director of Corneal Services and the Advanced OSD Clinic in Lexington, Kentucky. “TRYPTYR represents an important innovation—its fast onset and novel mechanism provide a new option to millions of dry eye patients.”
Committed to supporting ECPs with innovative products and educational resources, Alcon and its team of dedicated dry eye sales specialists have also launched an ECP campaign focusing on the speed of rapid natural tear production with TRYPTYR. The campaign features ECP tools, including videos and an interactive website along with a patient website. Additionally, Alcon recently hosted a national broadcast event for ECPs, featuring in-depth conversations surrounding this DED treatment option.
“TRYPTYR is an important milestone in the treatment of Dry Eye Disease, and I’m equally encouraged by Alcon’s commitment to supporting eye care as we continue to address the signs and symptoms of Dry Eye Disease for our patients,” said Preeya K. Gupta, MD, Triangle Eye Consultants in Raleigh, North Carolina. "Alcon is not only expanding the dry eye treatment options, but they are also supporting clinicians with the educational resources needed to confidently integrate new treatments like TRYPTYR into our practices.”
The U.S. launch will also coincide with expansive access initiatives, including a full Field Access Management team dedicated to assisting ECPs with fulfillment, and a First Fill Free trial program for eligible TRYPTYR patients. Additionally, ongoing copay support will be offered for refills for eligible patients.
In other company news, Alcon is the primary sponsor of the latest Tear Film & Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III report. The report, informed by 80 experts across 19 countries, offers an updated, evidence-based framework for diagnosing and managing DED. The report characterizes DED as a multifactorial condition defined by persistent symptoms and disruption of tear film stability and the ocular surface. It equips clinicians with refreshed diagnostic criteria, a personalized framework for treatment and expanded understanding of how sex and gender influence disease prevalence and patient care.
